CSL787 + Placebo

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Noncystic Fibrosis Bronchiectasis (NCFB)

Conditions

Noncystic Fibrosis Bronchiectasis (NCFB)

Trial Timeline

Dec 7, 2020 → Mar 12, 2023

NCT ID

NCT04643587

About CSL787 + Placebo

CSL787 + Placebo is a phase 1 stage product being developed by CSL for Noncystic Fibrosis Bronchiectasis (NCFB). The current trial status is completed. This product is registered under clinical trial identifier NCT04643587. Target conditions include Noncystic Fibrosis Bronchiectasis (NCFB).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07048262	Phase 2	Recruiting	Sep 3, 2025	Mar 28, 2028	Non-cystic Fibrosis Bronchiectasis
NCT04643587	Phase 1	Completed	Dec 7, 2020	Mar 12, 2023	Noncystic Fibrosis Bronchiectasis (NCFB)

Other Products from CSL

IgPro10Approved

four factor prothrombin complex concentrateApproved

Prothrombin complex concentrate (Human) + Fresh frozen plasma (FFP)Approved

IgPro10Approved

Blood coagulation Factor VIII and vWF, humanApproved